07:00 , May 5, 2014 |  BioCentury  |  Product Development

Targeted cargo

Taiwan Liposome Co. Ltd. and Ablynx N.V. are investigating whether combining their technologies can yield next-generation antibody-drug conjugates that deliver more molecules more precisely than existing ADC technologies. TLC manufactures liposomal formulations of the generic...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

Sustol regulatory update

Heron (formerly A.P. Pharma) said it will delay the resubmission of an NDA to FDA for Sustol to prevent chemotherapy-induced nausea and vomiting (CINV) to 2Q14 from 1Q14. The company said it received a notice...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Financial News

Heron Therapeutics financial update

Heron (formerly A.P. Pharma Inc. ) transferred its listing to NASDAQ and began trading under the symbol "HRTX." Previously, the stock traded on the OTC Bulletin Board. Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif.  ...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Financial News

Heron Therapeutics financial update

Heron implemented a 1-for-20 reverse stock split and changed its name from A.P. Pharma Inc. The company is seeking to list on NASDAQ. Following the split, the company has about 15 million shares outstanding. Heron...
08:00 , Jan 13, 2014 |  BioCentury  |  Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer  An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
08:00 , Jan 6, 2014 |  BioCentury  |  Finance

2014 Financial Markets Preview: Hoping the pause is brief

Bankers and buysiders are not expecting a repeat performance of biotech's stellar 2013. But the two dozen who spoke with BioCentury say the capital markets are primed to open back up this month, albeit on...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Financial News

A.P. Pharma completes follow-on

A.P. Pharma Inc. (OTCBB: APPA ), Redwood City, Calif.   Business: Drug delivery   Date completed: 11/20/13   Type: Follow-on   Raised: $60 million   Shares: 150 million   Price: $0.40   Shares after offering:...
08:00 , Nov 25, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) fell €4 (21%) to €15 on Friday after EMA's CHMP issued a negative opinion recommending against approval of an MAA for Masican masitinib to treat gastrointestinal stromal tumors (GIST)...
00:55 , Nov 21, 2013 |  BC Extra  |  Financial News

A.P. Pharma raises $60 million in follow-on

A.P. Pharma Inc. (OTCBB:APPA) raised $60 million through the sale of 150 million shares at $0.40 in a follow-on underwritten by Jefferies; Leerink Swan; JMP Securities; Brean Capital; and Oppenheimer. A.P. Pharma proposed the offering...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

A.P. Pharma management update

A.P. Pharma Inc. (OTCBB:APPA), Redwood City, Calif.   Business: Drug delivery   Hired: Brian Drazba as VP of finance and CFO, formerly VP of finance and chief accounting officer of Ista Pharmaceuticals Inc. , which...